Arcturus Therapeutics is trading 10.18% up now at $15.80 after presenting a scientific poster on its ARCT-810 mRNA therapy for OTC deficiency at the 2026 Annual Symposium of the Society for the Study of Inborn Errors of Metabolism today. - The presentation reinforces progress for ARCT-810, which previously completed Phase 2 enrollment and dosing, as announced in early August. - The company anticipates communicating additional study data and a regulatory plan for ARCT-810 later this quarter. - Shares previously closed 6.62% higher on August 24 and 22.38% higher on August 21, also supported by broader biotech-sector strength.